peopleInnovationCareers RarePipelineCollaborationFinanceAdvance treatment Skip to main contentSkip to navigationSkip to search
HNSA   ( ,  %) SEK
Quotes are delayed 15 minutes

Hansa Biopharma to present at the 39th Annual J.P. Morgan Healthcare Conference

23 Dec 2020, 08:00
The J.P. Morgan Healthcare Conference, the largest investment conference in the life science industry, will take place January 11-14, 2021

Lund, Sweden December 23, 2020. Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced that the Company’s management team will present at the 39th Annual J.P. Morgan Healthcare Conference 2021.

The company presentation will take place virtually Thursday January 14, 2021 at 7:30 am (EST)/13:30 (CET). 

Management will outline Hansa Biopharma’s proprietary enzyme technology platform as well as provide a status update on Idefirix® (imlifidase), which recently obtained conditional approval in the European Union for enabling kidney transplantation in highly sensitized kidney transplant patients. Imlifidase is additionally being evaluated for further use in other transplantation indications as well as investigated in autoimmune indications and as a pretreatment in gene therapy for inactivation of neutralizing antibodies.

Access to the presentation will be available under Events & Presentations on the Investors section of the company website at

Management will be available for meetings during the J.P. Morgan Conference week. Anne Marie Fields, RX Communication, NYC, will coordinate the schedule on behalf of Hansa Biopharma. Anne Marie can be reached through

In addition to the J.P. Morgan Conference, Hansa Biopharma has been invited to participate in the following conferences during the first half of 2021:

  • H.C. Wainwright BioConnect Conference on Monday January 11, 2021, with a presentation available at 6:00 am EST /12:00 CET) on the same day
  • SEB Healthcare Seminar on Monday January 18, 2021, with a presentation at 10:10 am CET on the same day
  • Vator Swiss-Nordic Healthcare Seminar on Thursday February 11, 2021
  • Carnegie Nordic Healthcare Seminar on Tuesday March 9, 2021
  • Kempen Life Science Conference, Wednesday May 5, 2021
  • RBC Global Healthcare Conference on Tuesday, May 19, 2021


For further information, please contact:
Klaus Sindahl, Head of Investor Relations
Hansa Biopharma 
Mobile: +46 (0) 709-298 269

Katja Margell
Head of Corporate Communications 
Hansa Biopharma 
Mobile: +46 (0) 768-198 326

About Hansa Biopharma
Hansa Biopharma is leveraging its proprietary enzyme technology platform to develop immunomodulatory treatments for enabling transplantations and rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection, gene therapy and cancer. The Company’s lead product candidate, imlifidase, is an antibody cleaving enzyme being developed to enable kidney transplantation in highly sensitized patients and may be further developed for use in other organ and tissue transplantation as well as acute autoimmune indications. Imlifidase has been granted conditional approval in the European Union for the desensitization treatment of highly sensitized adult kidney transplant patients with a positive crossmatch against an available deceased donor. Commercial launch in select European countries is expected in the fourth quarter of 2020. Hansa’s research and development program is advancing the Company’s enzyme technology to develop the next generation of IgG-cleaving enzymes with potentially lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases, gene therapy and oncology. Hansa Biopharma is based in Lund, Sweden and also has operations in other European countries and in the U.S.